The use of EMPA did not lower the LH secretion in our experimental model, but a previous study also showed that SGLT2i lowers androgen secretion not by acting on LH secretion, but by improving the activity of pancreatic beta cells with a reduced need for insulin and with a reduction in hyperinsulinemia, which are the main factors contributing to the increase in levels of testosterone in PCOS [68]. Here, INS is linked to polycystic ovary syndrome.